Optimizing Use of Tumor Necrosis Factor Inhibitors in the Management of Immune-Mediated Inflammatory Diseases
Brian Bressler(University of British Columbia), Alessandro Sette(La Jolla Institute for Immunology), Boulos Haraoui(Centre Hospitalier de l’Université de Montréal), Edward Keystone(University of Toronto)
Cited by 17
Related Papers
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
|Cell|2020|4k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
|New England Journal of Medicine|2000|1.8k
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.
|The Journal of Immunology|1994|851